Market Newsdesk

April 6, 2021 2:13 am

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. – IONS

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Ionis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 22, 2021, post-market, Ionis issued a press release announcing that “its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington’s disease (HD).” Ionis specified that “[t]he decision was based on the results of a pre-planned review of data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). While there were no new or emerging safety signals identified for tominersen, the iDMC made its recommendation based on the investigational therapy’s potential benefit/risk profile for study participants.”

On this news, Ionis’s stock price fell $12.05 per share, or 21.66%, to close at $43.59 per share on March 23, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ionis-pharmaceuticals-inc—ions-301262557.html

SOURCE Pomerantz LLP

April 6, 2021 2:08 am

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SoftBank Group Corporation – SFTBY

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of SoftBank Group Corporation (“SoftBank” or the “Company”) (OTCMKTS: SFTBY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether SoftBank and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 24, 2021, the short seller research site PlainSite posted a letter from the U.S. Securities and Exchange Commission (“SEC”) on Twitter, in response to a December 2020 Freedom of Information Act (“FOIA”) request, which revealed that SoftBank was the subject of an ongoing SEC investigation. The initial FOIA request sought information related to SoftBank’s trading of the securities of companies controlled by SoftBank Chief Executive Officer Masayoshi Son.

On this news, SoftBank’s stock price fell $2.30 per share, or 5.12%, to close at $42.65 per share on March 24, 2021.

Contact:

Robert S. Willoughby

Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-softbank-group-corporation—sftby-301262588.html

SOURCE Pomerantz LLP

April 6, 2021 2:04 am

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BlueCity Holdings Limited – BLCT

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of BlueCity Holdings Limited (“BlueCity” or the “Company”) (NASDAQ: BLCT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether BlueCity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On or around July 8, 2020, BlueCity conducted its initial public offering, issuing 5,300,000 American Depositary Shares (“ADSs”) priced at $16.00 per ADS. Then, on March 23, 2021, BlueCity issued a press release announcing its results for the fourth quarter of 2020. Among other results, BlueCity announced revenue of $42.7 million, missing consensus estimates by $3.92 million.

On this news, BlueCity’s ADS price fell $2.15 per ADS, or 26.71%, over the following two trading sessions, to close at $8.92 per ADS on March 24, 2021.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bluecity-holdings-limited—blct-301262556.html

SOURCE Pomerantz LLP

April 6, 2021 2:04 am

Ethernity Networks Powers Packet Processing in Tarana’s Breakthrough Fixed Wireless Product

PR Newswire

LOD, Israel, April 6, 2021 /PRNewswire/ — Ethernity Networks (AIM: ENET.L), a leading supplier of data processing offload solutions on programmable hardware for accelerating telco/cloud networks, announced today that it has started receiving production orders for its ENET Flow Processor FPGA systems-on-chip (SoCs) by Tarana Wireless, an American wireless broadband solution manufacturer. Ethernity FPGA SoCs provide complete IP networking functionality, including critical traffic management features, for Tarana’s ground-breaking Gigabit1 (G1) product.

Following a contract between Tarana and Ethernity signed in 2017, Ethernity has worked with Tarana and supported its development efforts, including multiple field trials, in bringing this innovative fixed mobile access product to mass adoption. Tarana is now fulfilling orders from service providers for large-scale commercial deployments of G1, requiring supply of 5,000 units of Ethernity’s ENET Flow Processor over the next 12 months. Further growth is expected in 2022.

Tarana has developed its unique radio access network technology from the ground up, including custom silicon for radio frequency and digital signal processing, specifically to address the significant shortcomings of prior attempts at fixed wireless using technology repurposed from other applications (i.e. indoor Wi-Fi and mobile cellular). Given its purpose-built design and numerous genuine industry firsts in RF signal processing, G1 can provide fiber-class service from installations on existing cellular tower assets in non-line-of-sight conditions — and in unlicensed spectrum — with performance and network economics 3x better than 5G for fixed broadband.

Ethernity has provided Tarana its equally unique silicon-tuned software, which, thanks to the efficiency of the ENET Flow Processor design, fits into low-cost FPGAs. Working in concert with Tarana’s radio technology in its tower-installed base nodes, the ENET Flow Processor provides advanced networking functions, traffic control, and management for up to 512 homes per ENET SoC.

“We are very pleased to see Tarana progressing with our ENET Flow Processor FPGA, through multiple field trials and now toward mass deployment of their product,” said David Levi, CEO of Ethernity Networks. “Our contribution to their G1 product helps carry intact their extremely high performance in the radio frequency domain into the IP domain, which we are confident will help this innovative technology gain additional traction with operators the world over. We are looking forward to supporting Tarana in their rapid commercial ramp.”

“Our collaboration with the Ethernity team has certainly made a significant contribution to our end-to-end system design,” noted Rakesh Tiwari, Tarana’s VP of Product Management. “Our ability to easily customize packet processing on the ENET platform to meet our application-specific needs has made it a superior choice over off-the-shelf ASIC-based switches.”

About Ethernity Networks

Ethernity Networks (AIM: ENET.L) provides innovative, comprehensive networking and security solutions on programmable hardware for accelerating telco/cloud networks. Ethernity’s FPGA logic offers complete Carrier Ethernet Switch Router data plane processing and control software with a rich set of networking features, robust security, and a wide range of virtual function accelerations to optimize telecommunications networks. Ethernity’s complete solutions quickly adapt to customers’ changing needs, improving time-to-market and facilitating the deployment of 5G, edge computing, and NFV.

About Tarana Wireless

Developed by a closely-knit team of 200+ seasoned engineers, Tarana’s patented and fundamental breakthroughs in radio access technology bring cellular wireless deployment simplicity to fiber-class fixed broadband for both mainstream and underserved markets, using both licensed and free, globally available, unlicensed spectrum. Tarana is headquartered in Milpitas, California, with additional research and development in Pune, India. For further information, please visit https://www.taranawireless.com

Ethernity Media and Analyst contact:
Kevin Tanzillo
Email: [email protected]
Tel: +1-903-865-1078

For Tarana Wireless, Inc.:
Steven Glapa, VP of Marketing
Tel: +1-408-351-4085

View original content:http://www.prnewswire.com/news-releases/ethernity-networks-powers-packet-processing-in-taranas-breakthrough-fixed-wireless-product-301262581.html

SOURCE Ethernity Networks

April 6, 2021 2:03 am

Ahold Delhaize share buyback update

Zaandam, the Netherlands, April 6, 2021 – Ahold Delhaize has repurchased 202,407 of Ahold Delhaize common shares in the period from March 29, 2021 up to and including April 1, 2021. The shares were repurchased at an average price of € 23.83 per share for a total consideration of € 4.8 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020.

The total number of shares repurchased under this program to date is 13,655,177 common shares for a total consideration of € 315.4 million.

Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/

This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.

April 6, 2021 2:03 am

Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3®

Study Investigates the Effects of Ventilatory Rescue Therapies on the Cerebral Oxygenation of COVID-19 Patients Using Masimo O3^®

Study Stresses the Importance of Brain Monitoring During the Treatment of Patients with Severe COVID-19

NEUCHATEL, Switzerland–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) today announced the results of a prospective, observational study published in Critical Care in which researchers in Genoa, Italy, evaluated the impact of a variety of rescue therapies on the systemic and cerebral oxygenation of mechanically ventilated COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).¹ To gauge the impact, the researchers used the Masimo Root^® Patient Monitoring and Connectivity Platform with O3^® Regional Oximetry, which uses near-infrared spectroscopy (NIRS) to enable monitoring of tissue oxygen saturation (rSO₂) in the region of interest, such as the brain.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210405005487/en/

Masimo Root® with O3® Regional Oximetry and SedLine® Brain Function Monitoring (Photo: Business Wire)

Dr. Chiara Robba and colleagues noted that “neurological complications are common in mechanically ventilated critically ill patients with COVID-19 and may lead to impaired cerebral hemodynamics,” and further, that respiratory rescue therapies “may have detrimental effects on brain physiology.” Observing, however, that there is currently little data available regarding the effect of rescue therapies on these patients’ brains, and in particular on cerebral oxygenation, the researchers sought to assess the impact of different ventilatory rescue therapies on the brain to help guide clinicians in choosing the most appropriate therapies for their COVID-19 patients.

The rescue therapies studied were recruitment maneuvers (RMs), prone positioning (PP), inhaled nitric oxide (iNO), and extracorporeal carbon dioxide removal (ECCO₂R). To assess impact, the researchers measured (before and after the application of each method) arterial oxygen saturation (SpO₂), partial pressure of oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂), and cerebral oxygen saturation (rSO₂). rSO₂ was obtained using Masimo Root with O3, which also allowed them to observe several additional parameters unique to Masimo O3: ΔO₂Hb, which monitors relative changes in the oxygenated hemoglobin component of rSO₂; ΔHHb, which monitors relative changes in the deoxygenated hemoglobin component of rSO₂; and ΔcHb, which monitors relative changes in total cerebral hemoglobin or blood volume. As a secondary aim, the researchers sought to evaluate the correlation between systemic and cerebral oxygenation.

The researchers found that the four rescue therapies had varied impact on cerebral oxygenation and the other measured parameters, noting in particular that after RMs, while there was no significant change in PaO₂ or PaCO₂, there was a significant decrease in rSO₂. After PP and after iNO therapies, both PaO₂ and rSO₂ increased; ΔcHb also increased, corresponding to increased cerebral blood volume. After ECCO₂R, both PaO₂ and rSO₂ decreased.

The researchers concluded, “Rescue therapies exert specific pathophysiological mechanisms, resulting in different effects on systemic and cerebral oxygenation in critically ill COVID-19 patients with ARDS. … The choice of rescue strategy to be adopted should take into account both lung and brain needs.”

They also noted, “To our knowledge, this is the first study investigating the early effects of rescue therapies on systemic and cerebral oxygenation and their correlation in critically ill patients with COVID-19-associated ARDS. The use of multimodal neuromonitoring, including new indices such as ΔHHbi + ΔO₂Hbi, enabled us to better investigate the specific consequences of each ventilatory rescue strategy for brain and lung function. This is particularly important, especially in the early phases after rescue therapies application, when most of the effects on cerebral physiology are mainly acting.”

Dr. Robba and study co-author Dr. Basil Matta, Senior Medical Director at Masimo, commented, “The ability to observe relative changes in oxygenated, deoxygenated, and total hemoglobin with O3’s delta indices provided us with better insight into why brain saturations change as a result of interventions, and allowed us to better understand the interactions between systemic and cerebral hemodynamics. For example, we saw that turning patients prone resulted in improved systemic and cerebral oxygenation, whereas the lung recruitment maneuver did not improve systemic oxygenation, and even had an adverse effect by reducing brain oxygen saturation.”

They continued, “Above all, the main objective of improving the oxygen content of the blood is to deliver oxygen to vital organs, the most important of which is the brain. Masimo O3 provides the clinician with the ability to assess the impact of any medical intervention aimed at improving oxygenation. O3’s hemoglobin indices were critical to our understanding of the effects of our interventions on the brain. Without such a monitor, we are at best guessing, and in danger of flying blind. As we continue to seek to improve care and outcomes for patients with severe COVID-19, any tool that helps us better understand the impact of different medical interventions is most welcome.”

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET^® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.² Masimo SET^® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,³ improve CCHD screening in newborns,⁴and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.^5-8Masimo SET^® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,⁹ and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S. News and World Report Best Hospitals Honor Roll.¹⁰ Masimo continues to refine SET^® and in 2018, announced that SpO₂ accuracy on RD SET^® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO₂ values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow^® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb^®), oxygen content (SpOC™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), Pleth Variability Index (PVi^®), RPVi™ (rainbow^® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root^® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine^® Brain Function Monitoring, O3^® Regional Oximetry, and ISA™ Capnography with NomoLine^® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters^® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7^® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat^® Rx, and devices available for use both in the hospital and at home, such as Rad-97^®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris^® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

Robba C, Ball L, Battaglini D, Cardim D, Moncalvo E, Brunetti I, Bassetti M, Giacobbe D, Vena A, Patroniti N, Rocco P, Matta B, Pelosi P. Early effects of ventilatory rescue therapies on systemic and cerebral oxygenation in mechanically ventilated COVID-19 patients with acute respiratory distress syndrome: a prospective observational study. Crit Care (2021)25:111. DOI: https://doi.org/10.1186/s13054-021-03537-1.
Published clinical studies on pulse oximetry and the benefits of Masimo SET^® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO₂ Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
Estimate: Masimo data on file.
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Root^® with O3^®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Root with O3, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005487/en/

Masimo

Evan Lamb

949-396-3376

[email protected]

KEYWORDS: Europe Switzerland United States North America California

INDUSTRY KEYWORDS: Medical Devices Infectious Diseases Hospitals Health Medical Supplies

MEDIA:

Logo

Photo

Masimo Root® with O3® Regional Oximetry and SedLine® Brain Function Monitoring (Photo: Business Wire)

April 6, 2021 2:03 am

Caledonia Mining Corporation Plc: Caledonia’s ‘Central Shaft’ Brought into Operation

ST HELIER, Jersey, April 06, 2021 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (“Caledonia” or the “Company”)(NYSE AMERICAN: CMCL; AIM: CMCL) is pleased to announce that its Central Shaft is now fully operational.

Commenting on the announcement, Steve Curtis, Chief Executive Officer, said:

“I am delighted to announce that our new Central Shaft, which is the deepest shaft of any gold mine in Zimbabwe, is fully operational. We can now start to hoist rock, men and material on a daily basis, which will solve our hoisting constraints and facilitate the planned expansion in mine capacity targeting 80,000 oz of gold production per year
¹
.

“Commissioning the Central Shaft has been the culmination of a six-year project costing approximately $67million, all funded through internal cash flow.

“This has been an owner-funded and built project by the Blanket team and I would like to thank everyone for their hard work and especially for achieving the completion of the shaft without any serious accidents, recording only two lost time injuries.”

For further information please contact:

Caledonia Mining Corporation Plc Mark Learmonth Camilla Horsfall	Tel: +44 1534 679 802 Tel: +44 7817 841793

WH Ireland Adrian Hadden/James Sinclair-Ford	Tel: +44 20 7220 1751

Blytheweigh Tim Blythe/Megan Ray	Tel: +44 207 138 3204

3PPB Patrick Chidley Paul Durham	Tel: +1 917 991 7701 Tel: +1 203 940 2538

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation (EU) No. 596/2014.

Cautionary Note Concerning Forward-Looking Information

Information and statements contained in this news release that are not historical facts are “forward-looking information” within the meaning of applicable securities legislation that involve risks and uncertainties relating, but not limited, to Caledonia’s current expectations, intentions, plans, and beliefs. Forward-looking information can often be identified by forward-looking words such as “anticipate”, “believe”, “expect”, “goal”, “plan”, “target”, “intend”, “estimate”, “could”, “should”, “may” and “will” or the negative of these terms or similar words suggesting future outcomes, or other expectations, beliefs, plans, objectives, assumptions, intentions or statements about future events or performance. Examples of forward-looking information in this news release include: production guidance, estimates of future/targeted production rates, and our plans and timing regarding further exploration and drilling and development. This forward-looking information is based, in part, on assumptions and factors that may change or prove to be incorrect, thus causing actual results, performance or achievements to be materially different from those expressed or implied by forward-looking information. Such factors and assumptions include, but are not limited to: failure to establish estimated resources and reserves, the grade and recovery of ore which is mined varying from estimates, success of future exploration and drilling programs, reliability of drilling, sampling and assay data, assumptions regarding the representativeness of mineralization being inaccurate, success of planned metallurgical test-work, capital and operating costs varying significantly from estimates, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects and other factors.

Security holders, potential security holders and other prospective investors should be aware that these statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. Such factors include, but are not limited to: risks relating to estimates of mineral reserves and mineral resources proving to be inaccurate, fluctuations in gold price, risks and hazards associated with the business of mineral exploration, development and mining, risks relating to the credit worthiness or financial condition of suppliers, refiners and other parties with whom the Company does business; inadequate insurance, or inability to obtain insurance, to cover these risks and hazards, employee relations; relationships with and claims by local communities and indigenous populations; political risk; risks related to natural disasters, terrorism, civil unrest, public health concerns (including health epidemics or outbreaks of communicable diseases such as the coronavirus (COVID-19)); availability and increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development, including the risks of obtaining or maintaining necessary licenses and permits, diminishing quantities or grades of mineral reserves as mining occurs; global financial condition, the actual results of current exploration activities, changes to conclusions of economic evaluations, and changes in project parameters to deal with unanticipated economic or other factors, risks of increased capital and operating costs, environmental, safety or regulatory risks, expropriation, the Company’s title to properties including ownership thereof, increased competition in the mining industry for properties, equipment, qualified personnel and their costs, risks relating to the uncertainty of timing of events including targeted production rate increase and currency fluctuations. Security holders, potential security holders and other prospective investors are cautioned not to place undue reliance on forward-looking information. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and various future events will not occur. Caledonia undertakes no obligation to update publicly or otherwise revise any forward-looking information whether as a result of new information, future events or other such factors which affect this information, except as required by law.

This news release is not an offer of the shares of Caledonia for sale in the United States or elsewhere. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the shares of Caledonia, in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such province, state or jurisdiction.

______________________

_{¹

Mr

Dana Roets (B

Eng

(Min.), MBA,

Pr.Eng

., FSAIMM, AMMSA), Chief Operating Officer, is the Company’s qualified person as defined by Canada’s National Instrument 43-101 and has approved any scientific or technical information contained in this news release.}

April 6, 2021 2:03 am

Caledonia Mining Corporation Plc: Caledonia declares another increased quarterly dividend

Highlights

Nine per cent increase from the previous quarterly dividend of 11 cents that was paid in January 2021
75 per cent cumulative increase from the level of 6.875 cents since October 2019
Fifth increase in the quarterly dividend since October 2019
Central Shaft brought into operation during the first quarter of 2021
Target production of 61,000 to 67,000 ounces of gold in 2021 and 80,000 ounces of gold per annum from 2022¹
Scheduled ramp up in production, a firm gold price and good cost control give the Board confidence that the business can sustain a higher level of dividend

Commenting on the announcement, Steve Curtis, Chief Executive Officer, said:

“We are pleased to announce an additional nine per cent increase in our quarterly dividend, the fifth increase in the past 18 months. This represents a cumulative 75 per cent rise in the dividend since the first increase in October 2019. The decision by the Board to increase the dividend reflects our continued confidence in the outlook for our business.

“As we reach the end of the six-year investment programme at Blanket Mine, the anticipated combination of rising production and declining capital investment gives us confidence to further increase the dividend payment in addition to providing funding for investment in new projects, including the exploration prospects at Glen Hume and Connemara North, as announced at the end of 2020.”

The relevant dates relating to the dividend are as follows:

Ex-dividend date: April 15, 2021
Record date: April 16, 2021
Payment date: April 30, 2021

Shareholders with a registered address in the UK will be paid in Sterling.

Caledonia’s Dividend Policy

Caledonia’s strategy to maximise shareholder value includes a quarterly dividend policy which the Board adopted in 2014. The Board will consider future increases in the dividend as appropriate in line with its prudent approach to risk management.

For further information please contact:

Caledonia Mining Corporation Plc Mark Learmonth Camilla Horsfall	Tel: +44 1534 679 802 Tel: +44 7817 841793

WH Ireland Adrian Hadden/James Sinclair-Ford	Tel: +44 20 7220 1751

Blytheweigh Tim Blythe/Megan Ray	Tel: +44 207 138 3204

3PPB Patrick Chidley Paul Durham	Tel: +1 917 991 7701 Tel: +1 203 940 2538

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation (EU) No. 596/2014.

________________________

_{¹

Mr

Dana Roets (B

Eng

(Min.), MBA,

Pr.Eng

., FSAIMM, AMMSA), Chief Operating Officer, is the Company’s qualified person as defined by Canada’s National Instrument 43-101 and has approved any scientific or technical information contained in this news release.}

April 6, 2021 2:03 am

Global Care Capital Announces LOI for Acquisition of CCM Technologies Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) — Global Care Capital Inc. (CSE:HLTH, FRANKFURT: L6V1) (the “Company” or “Global Care”) a global investment company which engages in early stage investment opportunities in private and public companies, is pleased to announce that it has entered into a letter of intent dated April 5^th, 2021 (the “LOI”), which sets out the basic terms and conditions for the acquisition by the Company of all of the issued and outstanding securities in the capital of CCM Technologies Inc. (Cryptocurrency Mining Technologies) (“CCM”), a cryptocurrency mining company with state of the art ASIC chips, in exchange for securities in Global Care (the “Transaction”).

The Company and CCM have entered into the LOI, which sets out certain terms and conditions pursuant to which the proposed Transaction will be completed. The terms outlined in the LOI are subject to the parties successfully entering into a definitive agreement (the “Definitive Agreement”) in respect of the Transaction on or before April 30^th, 2021 or such other date as the Company and CCM may mutually agree. The material terms of the Transaction are as follows:

In consideration for the Transaction, Global Care will issue an aggregate of 95,000,000 common shares of Global Care (the “Consideration Shares”) to CCM shareholders at a deemed price of $0.11 per Consideration Share and issue to CCM warrant holders an aggregate of 65,000,000 common share purchase warrants (the “Consideration Warrants”)
Each Consideration Warrant permits the holder thereof to acquire one Global Care common share at a price of $0.05 until 1 year after the closing of the transaction.
There is no hold period for the Consideration Shares or Consideration Warrants pursuant to applicable securities laws.

The Transaction is an arms-length transaction and no change in management, or the Board of Directors of Global Care is being contemplated at this time. The LOI also contemplates other material conditions precedent to the closing of the Transaction, including the completion of due diligence, compliance with all applicable regulatory requirements and receipt of all necessary regulatory, corporate, third-party, board and shareholder approvals being obtained, including the approval of the Canadian Securities Exchange. There can be no assurance that the Transaction will be completed as proposed, or at all.

“With the proposed acquisition of CCM Technologies, Global Care will expand its portfolio to include ASIC machines as CCM works toward implementing its first phase of a planned datacenter program. The machines can be used to test out proprietary mining software, improve hashrate and expand on existing analytics software. The team at CCM Technologies have proven they have a deep understanding of the industry,” said Alex Somjen, CEO of Global Care Capital.

The goal of the acquisition is to give Global Care shareholders further exposure to cryptocurrency mining infrastructure, which is the backbone and cornerstone of blockchain technology.

CCM Technologies Chief Executive Officer, Lawrence Cofield stated, “We are excited to work with Global Care at this important time in the crypto currency mining sector and create synergies by pairing our pipeline of opportunities and partnerships with leading hardware producers with Global Care’s existing exposure to crypto currency royalty streaming. There is potential to unlock value in numerous digital assets classes through innovative Decentralized Finance strategies (DeFi) with emerging blockchain technologies.”

About CCM Technologies Inc.

CCM Technologies Inc. is a digital asset technology company with a focus on providing infrastructure for the blockchain ecosystem and mining of cryptocurrencies.

Website: https://ccm-technologies.com

About Global Care

Global Care Capital is a global investment company which specializes in providing early-stage financing to private and public companies. The Company engages in new, early-stage investment opportunities in previously underdeveloped assets and obtaining positions in early-stage investment opportunities that adequately reflect the risk profile.

Website: https://globalcarecapital.com/

GLOBAL CARE CAPITAL INC.:

Company Contact:

Alex Somjen, President & CEO

604-687-2038

[email protected]

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The securities to be issued in connection with the Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

Cautionary Note

All information contained in this news release with respect to CCM was supplied by CCM for inclusion herein, and Global Care’s directors and officers have relied on CCM for such information.

Forward-Looking Information

: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on

www.sedar.com

April 6, 2021 1:58 am

Pomerantz Law Firm Announces the Filing of a Class Action against AgEagle Aerial Systems, Inc. and Certain Officers – UAVS

PR Newswire

NEW YORK, April 6, 2021 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against AgEagle Aerial Systems, Inc. (“AgEagle” or the “Company”) (NYSE: UAVS) and certain of its officers. The class action, filed in the United States District Court for the Central District of California, and docketed under 21-cv-01991, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise, acquired publicly traded AgEagle securities between September 3, 2019 and February 18, 2021, inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants’ violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

If you are a shareholder who purchased AgEagle securities during the Class Period, you have until April 27, 2021 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

[Click here for information about joining the class action]

AgEagle purports to be a commercial drone company. According to AgEagle’s website, the Company is engaged in the design, engineering, and manufacturing of commercial drones, as well as in providing drone services and solutions to the agriculture industry.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading because they misrepresented and failed to disclose the following adverse facts pertaining to the Company’s business, operations and prospects, which were known to Defendants or recklessly disregarded by them. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) AgEagle did not have a partnership with Amazon and in fact never had any relationship with Amazon; (2) rather than correct the public’s understanding about a partnership with Amazon, Defendants were actively contributing to the rumor that AgEagle had a partnership with Amazon; and (3) as a result, Defendants’ statements about AgEagle’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On October 14, 2020, news broke that Amazon did not have a partnership agreement with AgEagle, and in fact never did. The Wichita Business Journal published a story with the headline: “Exclusive: Who’s AgEagle’s big customer? We now know who it’s not.” The article reported that AgEagle was not partnering with Amazon.

On February 18, 2021, Bonitas Research published a report revealing that AgEagle “was a pump & dump scheme orchestrated by . . . AgEagle founder and former chairman Bret Chilcott and other UAVS insiders to defraud US investors.”

On this news, shares of AgEagle, fell $5.13, or 36.4%, to close at $8.96 on February 18, 2021, damaging investors.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980

View original content:http://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-ageagle-aerial-systems-inc–and-certain-officers–uavs-301262555.html

SOURCE Pomerantz LLP